Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Pharmacokinetic-Pharmacodynamic Modeling of Tolerance to the Prolactin-Secreting Effect of Chlorprothixene after Different Modes of Drug Administration

Metin Bagli, Richard Süverkrüp, Ralph Quadflieg, Gereon Höflich, Siegfried Kasper, Hans-Jürgen Möller, Michael Langer, Uwe Barlage and Marie Luise Rao
Journal of Pharmacology and Experimental Therapeutics November 1999, 291 (2) 547-554;
Metin Bagli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Süverkrüp
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph Quadflieg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gereon Höflich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siegfried Kasper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Jürgen Möller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Langer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Barlage
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Luise Rao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The objective of this study was the construction of a pharmacokinetic-pharmacodynamic model to describe the effects of chlorprothixene on prolactin secretion and the time-dependent alterations in the concentration-effect relationship due to tolerance development. Prolactin and chlorprothixene serum concentrations were determined in eight healthy men for up to 72 h after the intravenous and oral administration of chlorprothixene. An integrated pharmacokinetic model and a physiological indirect pharmacodynamic/tolerance model were applied to describe the prolactin-secreting effect of chlorprothixene. A three-compartment model served as pharmacokinetic model. The pharmacodynamic and tolerance model accounted for the baseline effect, the effect induced by the drug, and the regulatory mechanism that opposes the effect of the drug. This model adequately characterized the prolactin response after intravenous and oral drug administration of each individual by the sensitivity (dissociation constant), the efficacy (maximal prolactin secretion rate), the extent, and the rate of tolerance development. We speculate that this approach improves the quality of neuroendocrine challenge tests to determine the subject’s sensitivity to drugs and the time course of adaptation.

Footnotes

  • Send reprint requests to: Dr. Metin Bagli, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany. E-mail: bagli{at}uni-bonn.de

  • ↵FN1 Present address: Department of General Psychiatry, University of Vienna, Austria.

  • ↵FN2 Present address: Department of Psychiatry, Ludwig-Maximilian University, Munich, Germany.

  • Received for publication December 15, 1998.

  • Abbreviations:
    rin.prl
    prolactin secretion rate
    rin.prl.max
    maximal prolactin secretion rate
    rin.prl.p
    prolactin secretion rate without compensatory increase of T
    rin.prl.0
    baseline secretion rate of prolactin
    rin.prl.50
    prolactin secretion rate obtained by 50% inhibition of the prolactin-lowering effects of T
    rin.T
    secretion rate of T
    rin.T.0
    baseline secretion rate of T
    ccpx
    chlorprothixene concentration
    cda
    dopamine concentration
    cprl
    prolactin concentration
    cprl.p
    prolactin concentration that results from rin.prl.p
    css.prl.0
    cprl at baseline
    EC50
    dopamine concentration producing 50% rin.prl.max
    ET
    extent of tolerance
    IC50
    chlorprothixene concentration required to produce rin.prl.50
    IC50.p
    IC50without compensatory increase of T
    IC50.n
    IC50 with compensatory increase of T
    kel.prl
    prolactin elimination rate constant
    KI
    chlorprothixene dissociation constant at the dopamine D2 receptor
    ktol
    rate of tolerance development
    mprl
    mass of prolactin
    P
    proportionality factor
    T
    EC50-normalized dopamine concentration
    Tss.IC50n
    T at steady state forccpx = IC50.n
    Tss.IC50p
    T at steady state forccpx = IC50.p
    Tss.0
    T at baseline
    Vprl
    volume of distribution of prolactin
    • Accepted July 15, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 291 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 291, Issue 2
1 Nov 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacokinetic-Pharmacodynamic Modeling of Tolerance to the Prolactin-Secreting Effect of Chlorprothixene after Different Modes of Drug Administration
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Pharmacokinetic-Pharmacodynamic Modeling of Tolerance to the Prolactin-Secreting Effect of Chlorprothixene after Different Modes of Drug Administration

Metin Bagli, Richard Süverkrüp, Ralph Quadflieg, Gereon Höflich, Siegfried Kasper, Hans-Jürgen Möller, Michael Langer, Uwe Barlage and Marie Luise Rao
Journal of Pharmacology and Experimental Therapeutics November 1, 1999, 291 (2) 547-554;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Pharmacokinetic-Pharmacodynamic Modeling of Tolerance to the Prolactin-Secreting Effect of Chlorprothixene after Different Modes of Drug Administration

Metin Bagli, Richard Süverkrüp, Ralph Quadflieg, Gereon Höflich, Siegfried Kasper, Hans-Jürgen Möller, Michael Langer, Uwe Barlage and Marie Luise Rao
Journal of Pharmacology and Experimental Therapeutics November 1, 1999, 291 (2) 547-554;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Relationship among IC50, IC50.p, IC50.n, and Ki.
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Mechanisms of 5-Hydroxytryptamine2A Receptor Activation of the Mitogen-Activated Protein Kinase Pathway in Vascular Smooth Muscle
  • Interactive Role for Neurosteroids in Ethanol Enhancement of γ-Aminobutyric Acid-Gated Currents from Dissociated Substantia Nigra Reticulata Neurons
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics